PBAC recommends new Comirnaty NIP price

Pfizer secures backing for revised pricing of its Covid-19 vaccine as part of transition to NIP  The Pharmaceutical Benefits Advisory Committee (PBAC) has accepted a revised pricing for the National Immunisation Program (NIP) listing of Pfizer’s BNT162b2-platform Covid-19 vaccine.   The decision follows PBAC’s recommendation in December 2025, that Pfizer’s BNT162b2 platform (Comirnaty) vaccines, be listed on